- Home
- HAFN vs CORT Comparison
HAFN vs CORT Comparison
Compare HAFN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | CORT |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | HAFN | CORT |
|---|---|---|
| Price | $7.30 | $34.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $106.60 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | ★ 30.85 |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $675,040,000.00 |
| Revenue This Year | N/A | $23.03 |
| Revenue Next Year | N/A | $19.76 |
| P/E Ratio | ★ $11.39 | $56.16 |
| Revenue Growth | N/A | ★ 39.94 |
| 52 Week Low | $3.61 | $28.66 |
| 52 Week High | $7.33 | $117.33 |
Technical Indicators
Market Signals| Indicator | HAFN | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 81.40 | 30.61 |
| Support Level | $5.98 | $28.66 |
| Resistance Level | $6.75 | $40.51 |
| Average True Range (ATR) | 0.15 | 2.40 |
| MACD | 0.09 | 0.22 |
| Stochastic Oscillator | 97.33 | 36.69 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.